Cathepsin O (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Cathepsin O (CTSO; UniProt P43234) expressed in HEK293 cells. Suitable for proteolytic activity assays, inhibitor profiling, and antibody validation studies.
Expression system
HEK293
Cat. #
REC-CathepsinO

In stock

SKU
REC-CathepsinO
$498.00

Target Overview

Cathepsin O (CTSO; UniProt P43234) is a lysosomal cysteine protease of the papain superfamily encoded by the CTSO gene. The full-length human precursor spans 321 amino acids and undergoes propeptide processing to yield the mature, catalytically active enzyme. This recombinant form is produced in HEK293 mammalian cells, a system that supports the glycosylation patterns and folding environment characteristic of the native lysosomal enzyme — important considerations when generating material for inhibitor binding studies or conformation-sensitive antibody validation. Researchers use this recombinant in fluorogenic peptide-substrate cleavage assays to measure baseline proteolytic activity and to determine inhibitor potency (IC50) under defined pH conditions approximating the lysosomal environment. Because HEK293-expressed material retains post-translational modifications present in human tissue sources, it also serves as a well-defined positive control antigen in Western blot and immunohistochemistry validation workflows. The recombinant is validated for reactivity against human CTSO, with potential cross-reactivity predicted for mouse, rat, pan, and monkey orthologues based on sequence conservation — researchers should confirm orthologous activity experimentally for non-human applications. For antibody-based experiments, this recombinant pairs directly with Triple Point Biologics' matched Cathepsin O antibody (SKU: RP-CathepsinO), providing a defined antigen source for specificity confirmation, dot-blot titration, and immunodepletion controls. The combination of recombinant protein and matched antibody in a single-vendor workflow reduces a common source of lot-to-lot variability in antibody validation experiments.

Background

Cathepsin O is a lysosomal cysteine endopeptidase (EC 3.4.22.42) broadly expressed in human tissues. Classified within the papain-family clan CA, it is thought to contribute to the constitutive turnover of intracellular proteins in the lysosomal compartment, though its full substrate repertoire in physiological and pathological contexts remains an area of active investigation. Recent genetic and proteomic studies have positioned CTSO as a research target across several disease areas. Fréneau M et al. (2026, Cardiovasc Res) reported identification of rare missense variants in CTSO that reduce cathepsin O secretion in families with intracranial aneurysm, implicating altered extracellular cathepsin O activity in vascular wall biology and making recombinant material useful for variant functional characterisation assays. In parallel, Zhang C et al. (2026, Medicine (Baltimore)) applied Mendelian randomization and Bayesian colocalization to cathepsin family members — including CTSO — in the context of cardiovascular and pulmonary disease research, underscoring the value of well-characterised recombinant standards for proteomic calibration and plasma-level correlative studies. CTSO has also been studied as a research target in oncology. Tan L et al. (2025, Discov Oncol) used Mendelian randomization and bioinformatics approaches to investigate causal roles of cathepsin family members, including CTSO, across breast cancer subtypes, identifying associations that motivate further mechanistic work in cell-based and biochemical models where recombinant CTSO can serve as an activity reference. Separately, Yue H et al. (2025, Int J Gen Med) included CTSO among potential protein targets identified through integrated eQTL/pQTL analysis in sepsis research, a context where recombinant protein is relevant for target engagement assays. In metabolic disease research, Giraudi PJ et al. (2025, J Endocrinol Invest) identified cathepsin O among serum proteome signatures associated with liver steatosis in adolescents with obesity, a finding that supports its use as a biomarker-correlative standard in quantitative proteomics workflows. Across these published studies, recombinant CTSO expressed in a mammalian system provides the authentic post-translational context needed for enzymatic characterisation, inhibitor profiling, and use as a quantitative reference standard. Triple Point Biologics has produced proteinase and inhibitor research reagents since 1994; this recombinant reflects that depth of experience in lysosomal protease biology.

Applications

  • Fluorogenic peptide-substrate cleavage assay to measure Cathepsin O proteolytic activity under lysosomal pH conditions
  • Inhibitor IC50 determination in small-molecule screening campaigns targeting cysteine proteases
  • Positive control antigen for Western blot validation of anti-CTSO antibodies, paired with RP-CathepsinO
  • Dot-blot titration to establish antibody sensitivity and linearity for anti-CTSO immunodetection
  • Recombinant standard for absolute quantification of CTSO in proteomics and mass spectrometry workflows
  • Functional characterisation of CTSO missense variants identified in genetic studies of vascular or metabolic disease
  • Immunodepletion control to confirm antibody specificity in IHC or immunofluorescence experiments

References

  1. Fréneau M et al. Identification of rare missense variants reducing cathepsin O secretion in families with intracranial aneurysm. Cardiovasc Res. 2026. doi:10.1093/cvr/cvaf279. PMID: 41508845
  2. Zhang C et al. Novel treatment strategies for cardiovascular and pulmonary diseases: Insights from cathepsin-related Mendelian randomization and Bayesian colocalization. Medicine (Baltimore). 2026. doi:10.1097/MD.0000000000046963. PMID: 41496066
  3. Tan L et al. Causal roles of cathepsins family members in breast cancer subtypes: insights from Mendelian randomization and bioinformatics analysis. Discov Oncol. 2025. doi:10.1007/s12672-025-03787-3. PMID: 41123761
  4. Yue H et al. Identification of Potential Therapeutic Targets for Sepsis Using Mendelian Randomization and Integrated eQTL/pQTL Analysis. Int J Gen Med. 2025. doi:10.2147/IJGM.S535716. PMID: 41089542
  5. Giraudi PJ et al. Serum proteome signatures associated with liver steatosis in adolescents with obesity. J Endocrinol Invest. 2025. doi:10.1007/s40618-024-02419-x. PMID: 39017916

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Lysosome

Frequently Asked Questions

What molecular weight does recombinant Cathepsin O run at on SDS-PAGE or Western blot?

The full-length human CTSO precursor (UniProt P43234) is 321 amino acids with a predicted unprocessed MW of ~37 kDa. On reducing SDS-PAGE, the HEK293-expressed recombinant typically migrates at approximately 38–42 kDa due to N-linked glycosylation added by the mammalian expression system. Under denaturing WB conditions you may observe a diffuse or doublet band in this range reflecting glycoform heterogeneity. If you need a sharp, defined band for ladder calibration, treat the sample with PNGase F prior to electrophoresis to collapse glycoforms to the ~37 kDa core.

What processing form is this recombinant Cathepsin O — full-length precursor or mature active enzyme?

This recombinant is produced as the mature, catalytically active form following propeptide removal. HEK293 cells support the autocatalytic or trans-processing that cleaves the N-terminal propeptide (roughly residues 1–113 of the precursor), yielding the active enzyme domain. You should not expect a propeptide band in reducing SDS-PAGE. If your experimental model involves tracking propeptide processing as a readout, you would need to separately express the zymogen form — this product is not appropriate for that application.

What substrates does Cathepsin O cleave, and which fluorogenic peptide should I use in an activity assay?

Cathepsin O is a cysteine protease with a preference for substrates bearing hydrophobic residues at the P2 position, similar to other papain-family cathepsins. The fluorogenic substrate Z-Phe-Arg-AMC (carbobenzoxy-Phe-Arg-7-amino-4-methylcoumarin) is a well-established choice for initial activity confirmation at 1–10 µM substrate concentration. Release of AMC is monitored by excitation at 380 nm / emission at 460 nm. Cathepsin L also cleaves this substrate, so include a cathepsin-selective inhibitor (e.g., E-64 at 10 µM as a negative control) to confirm cysteine-protease-dependent signal.

What buffer conditions should I use for a Cathepsin O activity assay to approximate lysosomal pH?

For activity assays, use 50 mM sodium acetate, 1 mM EDTA, 2–5 mM DTT, pH 5.5. Pre-activate the enzyme by incubating in assay buffer with DTT for 10–15 minutes at 37°C before adding substrate — cysteine proteases require a reducing environment to maintain the active-site thiol in its reduced state. The storage buffer supplied (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol) maintains stability at -20°C but is not optimal for catalytic activity; dilute into pH 5.5 acetate buffer immediately before use. Avoid DMSO above 1% (v/v) in inhibitor dilutions.

What starting concentration of recombinant Cathepsin O should I use for an IC50 inhibitor assay?

A starting point of 5–20 nM recombinant Cathepsin O in the assay well is typical for IC50 determinations, keeping enzyme concentration well below the Ki of your inhibitor to avoid stoichiometric-binding artifacts. Use Z-Phe-Arg-AMC at a concentration bracketing the Km (empirically determined, but 10 µM is a reasonable starting estimate). Run an enzyme titration curve first to identify the linear range of AMC release over your assay window (30–60 min at 37°C, pH 5.5). For tight-binding inhibitors, drop enzyme to 1–2 nM and use Morrison's tight-binding IC50 equation.

Can I use Cathepsin O (Recombinant) as a positive control antigen for Western blot with the matched TPB antibody?

Yes — this recombinant is the recommended positive control for use with RP-CathepsinO (Triple Point Biologics rabbit polyclonal anti-Cathepsin O antibody; see /anti-cathepsin-o-rabbit-polyclonal-antibody). Both were developed in the same lab from the same antigen, so epitope compatibility is confirmed rather than predicted. Load 20–50 ng of recombinant Cathepsin O per lane alongside your cell lysate samples. The antibody is validated for Western blot, so you should see a clean band in the 38–42 kDa region. This is particularly useful when working with cell lines expressing low endogenous CTSO.

How much recombinant Cathepsin O should I load as a Western blot positive control to get a clean band?

Load 25–50 ng per lane as a starting point when using RP-CathepsinO at a 1:1,000–1:2,000 primary antibody dilution. This gives a clearly visible band without overwhelming the lane or cross-contaminating adjacent sample wells by diffusion. If you are optimizing antibody concentration, run a 2-fold dilution series of the recombinant (10, 25, 50, 100 ng) in parallel. Because HEK293-expressed material retains native glycosylation, the band position will closely match endogenous CTSO from human tissue or cell lysate, making it a reliable size reference as well as a signal control.

How should I store and handle recombinant Cathepsin O to preserve activity, and what is the shelf life?

Recombinant Cathepsin O is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol and shipped on dry ice. Upon receipt, aliquot immediately into single-use volumes and store at -20°C; avoid repeated freeze-thaw cycles, which progressively denature cysteine proteases. Under these conditions, activity is stable for at least 12 months from the date of manufacture (see CoA for lot-specific expiry). Do not dilute the stock into water or low-salt buffers for long-term storage — the glycerol and salt are critical cryoprotectants. Prepare working dilutions in pH 5.5 acetate assay buffer immediately before each experiment.

Validation imagery coming soon

Western blot validation figures for REC-CathepsinO will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →